Testimony Before the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee Regarding the Diabetes Drug Saxagliptin

View as PDF.

The Food and Drug Administration (FDA) should withdraw saxagliptin from the market because the large postmarket SAVOR trial demonstrated that the drug has unacceptable cardiovascular risks.